Recombinant factor VIIa in severe uremic bleeding.

Abstract

Activated recombinant factor VII (rFVIIa) has been successfully employed to control bleeding in haemophilia patients with inhibitors to factor VIII or IX (1) and in patients with thrombocytopenia (2). It has also been used for the treatment of a patient with abnormal platelet function (3). Until recently, repeated three-hourly doses were administered for a… (More)

Topics

  • Presentations referencing similar topics